Thursday, January 31, 2013

Isis Aces its Test

While there had been some doubt if�Isis (NASDAQ: ISIS  ) and its partner Sanofi (NYSE: SNY  ) would have their inherited cholesterol disorder drug Kynamro approved, news today that it received FDA approval shot Isis shares up 10%, while competitor Aegerion (NASDAQ: AEGR  ) was down 2% on the news. In this video, Motley Fool health-care analyst David Williamson tells us some of the headwinds and tailwinds investors can expect for the drug, and how well he sees it competing with Aegerion's Juxtapid in the same space.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report, "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of.�Click here now�to keep reading.

No comments:

Post a Comment